Journal of Clinical Oncology, Vol 19, Issue 19
(October), 2001: 3918-3928
© 2001 American Society for Clinical Oncology
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
By Mark S. Kaminski,
Andrew D. Zelenetz,
Oliver W. Press,
Mansoor Saleh,
John Leonard,
Louis Fehrenbacher,
T. Andrew Lister,
Robert J. Stagg,
George F. Tidmarsh,
Stew Kroll,
Richard L. Wahl,
Susan J. Knox,
Julie M. Vose
From the University of Michigan Medical Center, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, NY; University of Washington Medical Center and Corixa Corporation, Seattle, WA; University of Alabama, Birmingham, AL; Kaiser Northern California, Vallejo; Stanford University Medical Center, Stanford, CA; University of Nebraska Medical Center, Omaha, NE; and St Bartholomew’s Hospital, London, United Kingdom.
Address reprint requests to Mark S. Kaminski, MD, University of Michigan Cancer Center, 1500 E Medical Center Dr, Rm CCGC 4-316, Ann Arbor, MI 48109-0936; email: mkaminsk{at}umich.edu
PURPOSE: To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL) and to compare its efficacy to the patients’ last qualifying chemotherapy (LQC) regimens.
PATIENTS AND METHODS: Sixty patients who had been treated with at least two protocol-specified qualifying chemotherapy regimens and had not responded or progressed within 6 months after their LQC were treated with a single course of iodine I 131 tositumomab.
RESULTS: Patients had received a median of four prior chemotherapy regimens. A partial or complete response (CR) was observed in 39 patients (65%) after iodine I 131 tositumomab, compared with 17 patients (28%) after their LQC (P < .001). The median duration of response (MDR) was 6.5 months after iodine I 131 tositumomab, compared with 3.4 months after the LQC (P < .001). Two patients (3%) had a CR after their LQC, compared with 12 (20%) after iodine I 131 tositumomab (P < .001). The MDR for CR was 6.1 months after the LQC and had not been reached with follow-up of more than 47 months after iodine I 131 tositumomab. An independent review panel verified that 32 (74%) of the 43 patients with nonequivalent durations of response (> 30 days difference) had a longer duration of response after iodine I 131 tositumomab (P < .001). Only one patient was hospitalized for neutropenic fever. Five patients (8%) developed human antimurine antibodies, and one (2%) developed an elevated TSH level after treatment. Myelodysplasia was diagnosed in four patients in follow-up.
CONCLUSION: A single course of iodine I 131 tositumomab was significantly more efficacious than the LQC received by extensively pretreated patients with chemotherapy-refractory, low-grade, or transformed low-grade NHL and had an acceptable safety profile.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. A. Gregory, K. Hohloch, C. Gisselbrecht, K. Tobinai, and M. Dreyling
Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma
Oncologist,
October 1, 2009;
14(suppl_2):
4 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey, O. W. Press, and D. M. Goldenberg
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
Blood,
April 23, 2009;
113(17):
3891 - 3895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, D. J. Inwards, S. Spies, G. Wiseman, D. Patton, W. Erwin, A. W. Rademaker, B. B. Weitner, S. F. Williams, M. S. Tallman, et al.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 1, 2009;
27(10):
1653 - 1659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al.
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
Blood,
February 12, 2009;
113(7):
1412 - 1421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
J. Nucl. Med.,
January 1, 2009;
50(1):
8 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Iagaru, S. S. Gambhir, and M. L. Goris
90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment Imaging
J. Nucl. Med.,
November 1, 2008;
49(11):
1809 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Bishton, M. F. Leahy, R. J. Hicks, J. H. Turner, A. D. McQuillan, and J. F. Seymour
Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab
Ann. Onc.,
September 1, 2008;
19(9):
1629 - 1633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
August 7, 2008;
359(6):
613 - 626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ychou, D. Azria, C. Menkarios, P. Faurous, F. Quenet, B. Saint-Aubert, P. Rouanet, M. Pelegrin, C. Bascoul-Mollevi, D. Guerreau, et al.
Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer
Clin. Cancer Res.,
June 1, 2008;
14(11):
3487 - 3493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Bishton, R. J. Hicks, D. A. Westerman, M. H. Prince, M. Wolf, and J. F. Seymour
A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy
Haematologica,
May 1, 2008;
93(5):
789 - 790.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Toma and P. J. Medina
Update on Targeted Therapy--Focus on Monoclonal Antibodies
Journal of Pharmacy Practice,
February 1, 2008;
21(1):
4 - 16.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Khaibullina, B.-S. Jang, H. Sun, N. Le, S. Yu, V. Frenkel, J. A. Carrasquillo, I. Pastan, K. C.P. Li, and C. H. Paik
Pulsed High-Intensity Focused Ultrasound Enhances Uptake of Radiolabeled Monoclonal Antibody to Human Epidermoid Tumor in Nude Mice
J. Nucl. Med.,
February 1, 2008;
49(2):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans
Targeted therapy in nuclear medicine current status and future prospects
Ann. Onc.,
November 1, 2007;
18(11):
1782 - 1792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
J. Nucl. Med.,
November 1, 2007;
48(11):
1767 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pantelias, J. M. Pagel, N. Hedin, L. Saganic, S. Wilbur, D. K. Hamlin, D. S. Wilbur, Y. Lin, D. Stone, D. Axworthy, et al.
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
Blood,
June 1, 2007;
109(11):
4980 - 4987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
265 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. K. Tan, R. W. Wassenaar, and W. Zeng
Collimator Selection, Acquisition Speed, and Visual Assessment of 131I-Tositumomab Biodistribution in a Phantom Model
J. Nucl. Med. Technol.,
December 1, 2006;
34(4):
224 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Leahy, J. F. Seymour, R. J. Hicks, and J. H. Turner
Multicenter Phase II Clinical Study of Iodine-131-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
September 20, 2006;
24(27):
4418 - 4425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, and R. I. Fisher
Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911
J. Clin. Oncol.,
September 1, 2006;
24(25):
4143 - 4149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Pagel, Y. Lin, N. Hedin, A. Pantelias, D. Axworthy, D. Stone, D. K. Hamlin, D. S. Wilbur, and O. W. Press
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
Blood,
July 1, 2006;
108(1):
328 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
J. Clin. Oncol.,
February 10, 2006;
24(5):
823 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Czuczman
Controversies in Follicular Lymphoma: "Who, What, When, Where, and Why?" (Not Necessarily in That Order!)
Hematology,
January 1, 2006;
2006(1):
303 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Kaminski, J. A. Radford, S. A. Gregory, J. P. Leonard, S. J. Knox, S. Kroll, and R. L. Wahl
Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab
J. Clin. Oncol.,
November 1, 2005;
23(31):
7985 - 7993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, M. S. Kaminski, R. L. Wahl, S. J. Knox, A. D. Zelenetz, J. M. Vose, J. P. Leonard, S. Kroll, S. J. Goldsmith, and M. Coleman
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas
J. Clin. Oncol.,
October 20, 2005;
23(30):
7565 - 7573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. DeNardo, E. Tobin, K. Chan, B. M. Bradt, and S. J. DeNardo
Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies
Clin. Cancer Res.,
October 1, 2005;
11(19):
7075s - 7079s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Baranowska-Kortylewicz, M. Abe, K. Pietras, Z. P. Kortylewicz, T. Kurizaki, J. Nearman, J. Paulsson, R. L. Mosley, C. A. Enke, and A. Ostman
Effect of Platelet-Derived Growth Factor Receptor-{beta} Inhibition with STI571 on Radioimmunotherapy
Cancer Res.,
September 1, 2005;
65(17):
7824 - 7831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn, E. Cesarman, R. R. Furman, M. W. Schuster, R. Niesvizky, D. Muss, J. Fiore, et al.
Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma
J. Clin. Oncol.,
August 20, 2005;
23(24):
5696 - 5704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Richman, S. J. DeNardo, R. T. O'Donnell, A. Yuan, S. Shen, D. S. Goldstein, J. M. Tuscano, T. Wun, H. K. Chew, P. N. Lara, et al.
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody
Clin. Cancer Res.,
August 15, 2005;
11(16):
5920 - 5927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Rao, G. Akabani, and D. A. Rizzieri
Radioimmunotherapy for Non-Hodgkin's Lymphoma
Clin. Med. Res.,
August 1, 2005;
3(3):
157 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Linden, C. Hindorf, E. Cavallin-Stahl, W. A. Wegener, D. M. Goldenberg, H. Horne, T. Ohlsson, L. Stenberg, S.-E. Strand, and J. Tennvall
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
Clin. Cancer Res.,
July 15, 2005;
11(14):
5215 - 5222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Bennett, M. S. Kaminski, J. P. Leonard, J. M. Vose, A. D. Zelenetz, S. J. Knox, S. Horning, O. W. Press, J. A. Radford, S. M. Kroll, et al.
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
Blood,
June 15, 2005;
105(12):
4576 - 4582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P Levene, G. Singh, and C. Palmieri
Therapeutic monoclonal antibodies in oncology
J R Soc Med,
April 1, 2005;
98(4):
146 - 152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. W. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll, et al.
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
N. Engl. J. Med.,
February 3, 2005;
352(5):
441 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab
J. Clin. Oncol.,
February 1, 2005;
23(4):
712 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hagemeister, F. Cabanillas, M. Coleman, S. A. Gregory, and P. L. Zinzani
The Role of Mitoxantrone in the Treatment of Indolent Lymphomas
Oncologist,
February 1, 2005;
10(2):
150 - 159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, P. J. Bierman, C. Enke, J. Hankins, G. Bociek, J. C. Lynch, and J. O. Armitage
Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 20, 2005;
23(3):
461 - 467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Michel, A. V. Rosario, P. M. Andrews, D. M. Goldenberg, and M. J. Mattes
Therapy of Small Subcutaneous B-Lymphoma Xenografts with Antibodies Conjugated to Radionuclides Emitting Low-Energy Electrons
Clin. Cancer Res.,
January 15, 2005;
11(2):
777 - 786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Z. Lin, M. A. Teitell, and G. J. Schiller
The Evolution of Antibodies into Versatile Tumor-Targeting Agents
Clin. Cancer Res.,
January 1, 2005;
11(1):
129 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard
Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates
Hematology,
January 1, 2005;
2005(1):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Larson and E. P. Krenning
A Pragmatic Perspective on Molecular Targeted Radionuclide Therapy
J. Nucl. Med.,
January 1, 2005;
46(1_suppl):
1S - 3S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey and D. M. Goldenberg
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
J. Nucl. Med.,
January 1, 2005;
46(1_suppl):
115S - 127S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. S. Jhanwar and C. Divgi
Current Status of Therapy of Solid Tumors
J. Nucl. Med.,
January 1, 2005;
46(1_suppl):
141S - 150S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac
FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
RadioGraphics,
January 1, 2005;
25(1):
191 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. DiJoseph, M. E. Goad, M. M. Dougher, E. R. Boghaert, A. Kunz, P. R. Hamann, and N. K. Damle
Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
Clin. Cancer Res.,
December 15, 2004;
10(24):
8620 - 8629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Davis, M. S. Kaminski, J. P. Leonard, F. J. Hsu, M. Wilkinson, A. Zelenetz, R. L. Wahl, S. Kroll, M. Coleman, M. Goris, et al.
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
Clin. Cancer Res.,
December 1, 2004;
10(23):
7792 - 7798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-L. Law, C. G. Cerveny, K. A. Gordon, K. Klussman, B. J. Mixan, D. F. Chace, D. L. Meyer, S. O. Doronina, C. B. Siegall, J. A. Francisco, et al.
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20-Auristatin Conjugates
Clin. Cancer Res.,
December 1, 2004;
10(23):
7842 - 7851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Kaminski, A. D. Zelenetz, O. W. Press, M. N. Saleh, J. P. Leonard, L. Fehrenbacher, T. A. Lister, S. Kroll, R. L. Wahl, S. J. Knox, et al.
Tositumomab and Iodine I 131 Tositumomab (The BEXXAR(R) Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin's Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
2631 - 2631.
[Abstract]
|
|
|
|
|
|
|
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al.
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results
Clin. Cancer Res.,
August 15, 2004;
10(16):
5327 - 5334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Forero, P. L. Weiden, J. M. Vose, S. J. Knox, A. F. LoBuglio, J. Hankins, M. L. Goris, V. J. Picozzi, D. B. Axworthy, H. B. Breitz, et al.
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Blood,
July 1, 2004;
104(1):
227 - 236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi, S. A. Pileri, and P. L. Zinzani
Challenging paradigms in lymphoma treatment
Ann. Onc.,
May 1, 2004;
15(5):
703 - 711.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Advani, S. A. Rosenberg, and S. J. Horning
Stage I and II Follicular Non-Hodgkin's Lymphoma: Long-Term Follow-Up of No Initial Therapy
J. Clin. Oncol.,
April 15, 2004;
22(8):
1454 - 1459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.J. Davies, A.Z.S. Rohatiner, S. Howell, K.E. Britton, S.E. Owens, I.N. Micallef, D.P. Deakin, B.M. Carrington, J.A. Lawrance, S. Vinnicombe, et al.
Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 15, 2004;
22(8):
1469 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose
Bexxar(R): Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma
Oncologist,
April 1, 2004;
9(2):
160 - 172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, R. D. Gascoyne, and K. Van Besien
Low-Grade Lymphoma
Hematology,
January 1, 2004;
2004(1):
203 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al.
Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response?
J. Nucl. Med.,
December 1, 2003;
44(12):
2000 - 2018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Lister
High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When?
J. Clin. Oncol.,
November 1, 2003;
21(21):
3894 - 3896.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, T. A. Gooley, D. G. Maloney, S. H. Petersdorf, J. F. Eary, J. G. Rajendran, S. A. Bush, L. D. Durack, J. Golden, P. J. Martin, et al.
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
Blood,
October 1, 2003;
102(7):
2351 - 2357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Rossi, R. M. Sharkey, W. McBride, H. Karacay, L. Zeng, H. J. Hansen, D. M. Goldenberg, and C.-H. Chang
Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy
Clin. Cancer Res.,
September 1, 2003;
9(10):
3886s - 3896s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. M. Sharkey, H. Karacay, H. Richel, W. J. McBride, E. A. Rossi, K. Chang, D. Yeldell, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg
Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy
Clin. Cancer Res.,
September 1, 2003;
9(10):
3897s - 3913s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. J. DeNardo, G. L. DeNardo, A. Yuan, C. M. Richman, R. T. O'Donnell, P. N. Lara, D. L. Kukis, A. Natarajan, K. R. Lamborn, F. Jacobs, et al.
Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT
Clin. Cancer Res.,
September 1, 2003;
9(10):
3938s - 3944s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. L. DeNardo, G. R. Mirick, L. A. Kroger, B. M. Bradt, K. R. Lamborn, and S. J. DeNardo
Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies
Clin. Cancer Res.,
September 1, 2003;
9(10):
4013s - 4021s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, E. R. Gaynor, S. E. Rivkin, and R. I. Fisher
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
Blood,
September 1, 2003;
102(5):
1606 - 1612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig, C. A. White, L. I. Gordon, G. A. Wiseman, C. Emmanouilides, J. L. Murray, J. Lister, and P. S. Multani
Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 1, 2003;
21(7):
1263 - 1270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Buchsbaum and A. F. LoBuglio
Targeting of 125I-Labeled B Lymphocyte Stimulator
J. Nucl. Med.,
March 1, 2003;
44(3):
434 - 436.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med.,
February 1, 2003;
44(2):
224 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sgouros, S. Squeri, A. M. Ballangrud, K. S. Kolbert, J. B. Teitcher, K. S. Panageas, R. D. Finn, C. R. Divgi, S. M. Larson, and A. D. Zelenetz
Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin's Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose-Response
J. Nucl. Med.,
February 1, 2003;
44(2):
260 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell, K. M. Ristow, T. M. Habermann, G. A. Wiseman, and T. E. Witzig
Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
September 15, 2002;
20(18):
3885 - 3890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Seldin
Techniques for Using Bexxar for the Treatment of Non-Hodgkin's Lymphoma*
J. Nucl. Med. Technol.,
September 1, 2002;
30(3):
109 - 114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. O. Dillman
Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
J. Clin. Oncol.,
August 15, 2002;
20(16):
3545 - 3557.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Michel and M. J. Mattes
Intracellular Accumulation of the Anti-CD20 Antibody 1F5 in B-Lymphoma Cells
Clin. Cancer Res.,
August 1, 2002;
8(8):
2701 - 2713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig, L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, et al.
Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
May 15, 2002;
20(10):
2453 - 2463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson
CHOP plus Rituximab -- Balancing Facts and Opinion
N. Engl. J. Med.,
January 24, 2002;
346(4):
280 - 282.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology,
January 1, 2002;
2002(1):
241 - 262.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. D. Cheson
Some Like It Hot!
J. Clin. Oncol.,
October 1, 2001;
19(19):
3908 - 3911.
[Full Text]
|
|
|
|
